16 studies were found.

1.		Recruiting	Avastin/Placebo + Tarceva or Taxotere for Second-line Advanced Non-small Cell Lung Cancer Conditions: Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Adenocarcinoma; Carcinoma, Large Cell
2.		Completed	Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer Conditions: SCLC; Carcinoma, Small Cell
3.		Completed	Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors Conditions: stage II pancreatic cancer; stage III pancreatic cancer; recurrent pancreatic cancer; unspecified adult solid tumor, protocol specific; ...
4.		Recruiting	Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Condition: Carcinoma, Non-Small Cell Lung
5.		Recruiting	Erlotinib in Treating Patients with Advanced Non-Small Cell Lung Cancer Condition: Carcinoma, Non-Small-Cell Lung
6.		Recruiting	Erlotinib vs. Standard Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer and an Eastern Cooperative Oncology Group Performance Status of 2 Condition: Non-Small Cell Lung Carcinoma
7.		Completed	OSI-774 (Tarceva) in Treating Patients with Stage III or Stage IV Non-Small Cell Lung Cancer Condition: Carcinoma, Non-Small-Cell Lung
8.		No longer recruiting	OSI-774 (Tarceva) Plus Gemcitabine in Patients with Locally Advanced, Unresectable or Metastatic Pancreatic Cancer. Condition: Pancreatic Cancer
9.		No longer recruiting	OSI-7904L in Patients with Gastric or Gastroesophageal (GEJ) Cancer Conditions: Gastroesophageal Adenocarcinoma; Gastric Adenocarcinoma
10.		Not yet recruiting	OSI-7904L versus 5-FU/LV as Treatment in Patients with Biliary Tract Cancer Condition: Bilary Tract Cancer
11.		No longer recruiting	Phase II Study of CP-461 in Patients with Advanced Renal Cell Cancer Condition: Renal Cell Carcinoma
12.		No longer recruiting	Phase II Study of Taxotere in Combination with Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients Condition: NSCLC
13.		No longer recruiting	A Pilot Study of OSI-461 in Patients with Chronic Lymphocytic Leukemia (CLL) Condition: Chronic Lymphocytic Leukemia
14.		No longer recruiting	A Pilot Trial of CP-461 in Patients with Chronic Lymphocytic Leukemia Conditions: Chronic Lymphocytic Leukemia; Leukemia
15.		Completed	Study of OSI-211 vs. Topotecan in Patients with Relapsed Epithelial Ovarian Cancer Condition: Ovarian Neoplasms
16.		No longer recruiting	Taxotere/Aptosyn versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients Condition: Non-small cell lung cancer